Dialog Box

Loading...
19
Nov
2019

More patients on clinical trials

A/Prof Nick Gottardo, Cure Brain Cancer Foundation Innovation Grant recipient

The trial, called SJ-ELiOT, will recruit patients in Australia, the USA, and Germany.

The Australian arm of his SJ-ELiOT clinical trial will be funded under the Australian Brain Cancer Mission (ABCM) – a $127 million Government-backed plan to double brain cancer survival in ten years and improve patients’ quality of life.

A/Prof Gottardo’s work at the Telethon Kids Institute in Perth, was recently recognised by his peers, who named him 2019 Collaborative Researcher of the Year. 

This prestigious award is decided by a panel, comprised of members of the DIPG (diffuse intrinsic pontine glioma) Collaborative – an international body of 29 leading brain cancer organisations, including Cure Brain Cancer Foundation.  

On his Cure Brain Cancer Foundation-backed project alone he collaborates with 20 researchers at seven institutes, helping to design an additional project in collaboration with Prof Brandon Wainwright from the Institute for Molecular Bioscience in Queensland. Prof Brandon Wainwright is also the recipient of the $150,000 Cure Brain Cancer Foundation John Trivett Fellowship for Brain Cancer and is helping A/Prof Nick Gottardo with the brain cancer models used in his research.

In addition, A/Prof Nick Gottardo and Dr Raelene Endersby (also at Telethon Kids Institute) have collaborated with researchers at St Jude Children’s Research Hospital (USA) and the German National Cancer Centre to create a collaborative group consisting of researchers and clinicians across three continents, to support the development of an international clinical trial for medulloblastoma, the first ever designed collaboratively and open to patient enrolment across three continents.

“These studies have two important outcomes for children with medulloblastoma. Firstly, we have identified a new combinatorial therapy that appears to enhance radiation-induced G3 MB cell death, and this resulted in significant improvements in survival.” 

“The rarity of medulloblastoma requires that clinical trials only evaluate the most promising treatments. This is because our patient numbers are few, and maintaining quality of life for patients and their families is imperative”

Help fund more ground-breaking research like this